New hope for controlling rare genetic tumors
NCT ID NCT04374305
Summary
This study is testing two repurposed cancer drugs, brigatinib and neratinib, to see if they can slow or stop the growth of tumors in people with NF2-related schwannomatosis. It will enroll about 100 participants aged 12 and older who have specific, growing tumors. The trial uses a flexible 'basket' design, allowing participants to potentially try different treatments if their first one stops working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.